Clinical Study of Fangji Huangqi Decoction in Treating Chronic Heart Failure

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054580

Enrollment

Unknown

Registered

2021-12-20

Start date

2021-12-21

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Control group:Western medicine routine treatment

Experimental group:Traditional western medicine treatment plus Fangji Huangqi Decoction

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Western medicine for chronic heart failure; 2. Comply with the syndrome differentiation standard of TCM chronic heart failure with qi deficiency and blood stasis and water-drinking stop syndrome; 3. LVEF450ng/l; 4. The NYHA classification of cardiac function is II~III; 5. Gender is not limited; 6. Aged 18 to 85 years; 7. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute coronary syndrome, acute myocardial infarction within 6 months, patients with revascularization within the past 6 months, or patients planning to undergo revascularization within the past 1 week, cardiogenic shock, fatal arrhythmia, myocardial disease, rheumatic heart valve disease, myocarditis, constrictive pericarditis, pulmonary embolism, etc.; 2. Severe hepatic and renal insufficiency; 3. Combined with serious primary diseases such as endocrine system and hematopoietic system; 4. Women who are planning to give birth, pregnancy or lactation in the past 3 months; 5. Mental patients; 6. Those with allergies, or those who are known to be allergic to this medicine and its ingredients; 7. Those who have participated in other clinical trials within the past 3 months. 8. The investigator judges that the survival period does not exceed 3 months; 9. Those who judge that the researcher cannot complete the research or comply with the requirements of the research.

Design outcomes

Primary

Measure	Time frame
Kansas City Cardiomyopathy Quality of Life Scale;	—

Secondary

Measure	Time frame
6 minute walk test distance;Echocardiogram;N-terminal pro-B-type natriuretic peptide;Heart function classification ;	—

Countries

China

Contacts

Public ContactZhao Yingqiang

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

zhaoyingqiang1000@126.com+86 13920089969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026